Exalt Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 22-06-2024
- Paid Up Capital ₹ 0.50 M
as on 22-06-2024
- Company Age 10 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 M
as on 22-06-2024
- Revenue 4.87%
(FY 2022)
- Profit 29.85%
(FY 2022)
- Ebitda 32.52%
(FY 2022)
- Net Worth 25.12%
(FY 2022)
- Total Assets 16.67%
(FY 2022)
About Exalt Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.50 M.
Veena Gupta and Bhola Gupta serve as directors at the Company.
- CIN/LLPIN
U24100HR2014PTC053831
- Company No.
053831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Faridabad, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Exalt Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veena Gupta  | Director | 24-Nov-2014 | Current |
| Bhola Gupta | Director | 24-Nov-2014 | Current |
Financial Performance of Exalt Pharmaceuticals.
Exalt Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 4.87% increase. The company also saw a substantial improvement in profitability, with a 29.85% increase in profit. The company's net worth Soared by an impressive increase of 25.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Exalt Pharmaceuticals?
In 2021, Exalt Pharmaceuticals had a promoter holding of 88.00% and a public holding of 12.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Gargill Infrastructure Private LimitedActive 5 years 9 months
Veena Gupta and Bhola Gupta are mutual person
- Novotel Pharmaceuticals Private LimitedActive 4 years 1 month
Veena Gupta and Bhola Gupta are mutual person
- Glato Foodgrains Private LimitedActive 3 years 3 months
Veena Gupta and Bhola Gupta are mutual person
- Significant Fashion Private LimitedActive 6 years 1 month
Veena Gupta and Bhola Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 11 Mar 2015 | ₹7.50 M | Open |
How Many Employees Work at Exalt Pharmaceuticals?
Unlock and access historical data on people associated with Exalt Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Exalt Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Exalt Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
